Where does Fimbrion Therapeutics, Inc rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Fimbrion Therapeutics, Inc ranks #46,722 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Fimbrion Therapeutics, Inc hold?

Fimbrion Therapeutics, Inc holds 5 US utility patents granted between 2020 and 2025, spanning 6 technology areas.

What is Fimbrion Therapeutics, Inc's Innovation Score?

Fimbrion Therapeutics, Inc has an Innovation Score of 25.1 out of 100 (16th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Fimbrion Therapeutics, Inc's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Fimbrion Therapeutics, Inc.

What does claim depth mean for Fimbrion Therapeutics, Inc's patents?

Fimbrion Therapeutics, Inc's patents average 11.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Fimbrion Therapeutics, Inc patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Fimbrion Therapeutics, Inc

Q: What technology areas does Fimbrion Therapeutics, Inc focus on?

Fimbrion Therapeutics, Inc's top technology area is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids) with 5 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Fimbrion ranks #46,722 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#46,722
of 49,997 US assignees by volume: 16th percentile
by Innovation Score (25.1/100): 11.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R46722 · US Corporation #46,722 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #46,722/49,997
PHOTO-FINISH Fillmaster Systems
CPC-NARROW C07H · 6 areas
INNOV-THIN 25.1/100
CLAIMS-PAR 11.6 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Fillmaster Systems, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Aviex Textnologies · near

25
Fimbrion Therapeutics · this assignee

25
LifeQode · near

25
Rock River Arms · near

25
Temple University · near

25
3D Lighting… · lowest

7

What this shows Fimbrion's Innovation Score is 25.1/100 (16th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Fimbrion's grants concentrate

Fimbrion Therapeutics, Inc is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids). By volume, Fimbrion sits between Fillmaster Systems, LLC and Finishing Brands Holdings Inc..

Fimbrion's three-year grant acceleration

Fimbrion Therapeutics, Inc shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Fillmaster Systems

5
Filmic

5
Filtermag Interna…

5
Filtrona Filter P…

5
Finding Rover

5
Finicity

5
Finish Thompson

5
Finishing Brands…

5
Fimbrion Therapeu… ◀

5

What this shows Fimbrion holds 5 patents at rank #46,845, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Fimbrion

By rank, the assignees closest to #46,845 in granted patent volume.

Leaders in C07H (Sugars)

Other assignees with the most granted patents in Fimbrion's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Fimbrion, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (25 here).

LifeQode, LLC 25 Aviex Textnologies LLC 25 Temple University 25 Rock River Arms, Inc. 25

Fimbrion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 16th percentile higher than 16% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Fimbrion Therapeutics, Inc patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	20.0%
2021	1	20.0%
2023	1	20.0%
2025partial year	2	40.0%

Which technologies does Fimbrion Therapeutics, Inc patent most?

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07D - Heterocyclic Compounds 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 1

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#46,722

of 49,997 tracked assignees

Innovation Score

25.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Fimbrion Therapeutics, Inc's patent record in context - here's where to go next.

Fimbrion Therapeutics, Inc's lead technology class is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids), 100% of its portfolio - see every assignee active in that class. Explore C07H
Ranked #46,722 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Fimbrion Therapeutics, Inc against Fillmaster Systems, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.